Related Experiment Video
Updated: Jul 16, 2026
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Combined MMF and insulin therapy prevents renal injury in experimental diabetic rats
Xiaoyan Wu1, Dongqing Zha, Guangsheng Xiang
1Division of Nephrology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, People's Republic of China.
Abstract:
Conventional therapies for diabetic mellitus are not effective in preventing the progression from early diabetic nephropathy (DN) to end-stage renal disease. The role of inflammation in the pathogenesis of DN has been implicated both clinically and experimentally, which provides an alternative therapeutic target for DN. Anti-inflammatory impact of mycophenolate mofetil (MMF) alone and in combination with insulin had been observed in a rat model of experimental DN. In this study, the diabetic rats were subjected to different treatments. Compared to control, the expression levels of CD68, NGF, and NF-kappaB p65, as determined immunohistochemically, were elevated in diabetic rats. Treatment with combined MMF/insulin is associated with a significant reduction in renal tissue of NGF and NF-kappaB p65 expression, macrophage infiltration. It also partially improved the renal function and attenuated renal hypertrophy at early stage of DN. CD68 was found to positively correlate with urinary albumin excretion and NGF. The combined use of MMF/insulin seemed to offer more protections in rats with experimental diabetic renal injury, and the protective effects of MMF might be due to its anti-inflammatory actions through inhibition of NF-kappaB activation and reduction of T cells and macrophage infiltration and/or other kidney chemokine productions.
Insights
Mycophenolate mofetil (MMF) combined with insulin shows promise in treating diabetic nephropathy (DN). This combination therapy reduced inflammation and improved kidney function in diabetic rats, offering a potential new treatment strategy for DN.
Area of Science:
- Nephrology
- Endocrinology
- Immunology
Background:
- Diabetic nephropathy (DN) is a progressive kidney disease often unresponsive to conventional therapies.
- Inflammation plays a critical role in DN pathogenesis, presenting a potential therapeutic target.
- Mycophenolate mofetil (MMF) has demonstrated anti-inflammatory effects.
Purpose of the Study:
- To investigate the therapeutic potential of MMF in combination with insulin for experimental diabetic nephropathy.
- To evaluate the effects of this combination therapy on inflammatory markers and renal function in diabetic rats.
Main Methods:
- Diabetic rats were treated with MMF and insulin, alone or in combination.
- Immunohistochemistry was used to assess the expression of CD68, NGF, and NF-kappaB p65.
- Renal function and hypertrophy were evaluated.
Main Results:
- Combined MMF/insulin treatment significantly reduced renal expression of NGF and NF-kappaB p65.
- Macrophage infiltration was decreased, and renal function was partially improved.
- CD68 expression correlated positively with urinary albumin excretion and NGF levels.
Conclusions:
- Combined MMF/insulin therapy offers protective effects in experimental diabetic renal injury.
- MMF's anti-inflammatory actions, including NF-kappaB inhibition and reduced immune cell infiltration, likely contribute to its protective effects.
- This combination therapy may represent a novel strategy for managing early-stage DN.
More Related Videos
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
08:15Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
